**Question:** All are true about Exenatide except a€™.

A. Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
B. Exenatide is a synthetic drug derived from the venom of Gila monster, a venomous lizard.
C. Exenatide stimulates insulin secretion in a glucose-dependent manner.
D. Exenatide is a potent inhibitor of glucagon secretion.

**Core Concept:**
Exenatide is a synthetic drug that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is an incretin hormone secreted by the intestinal L cells in response to food intake, which promotes insulin release while suppressing glucagon secretion. Exenatide is derived from the venom of the Gila monster, a venomous lizard, and is used as an anti-diabetic medication.

**Why the Correct Answer is Right:**
Option A is correct because Exenatide is a synthetic drug that acts as a GLP-1 receptor agonist, mimicking the action of endogenous GLP-1. GLP-1 stimulates insulin release in a glucose-dependent manner, which is beneficial for diabetes management.

Option B is incorrect because Exenatide is a synthetic drug derived from the venom of the Gila monster, not a naturally occurring substance. The option misrepresents the origin of Exenatide.

Option C is correct as Exenatide promotes insulin secretion in a glucose-dependent manner, making it an effective tool in managing diabetes.

Option D is incorrect because Exenatide primarily acts as a GLP-1 receptor agonist and does not directly inhibit glucagon secretion. Although it may indirectly suppress glucagon by promoting insulin release, the primary action is GLP-1 receptor activation, not glucagon inhibition.

**Why Each Wrong Option is Incorrect:**
Option B, although misleading, is incorrect because Exenatide is a synthetic drug, not a naturally occurring substance. The correct source of Exenatide is the Gila monster's venom, not the pancreas.

Option D is incorrect because Exenatide primarily acts as a GLP-1 receptor agonist. While it may suppress glucagon indirectly through enhanced insulin release, its primary action is on GLP-1 receptors, not on glucagon.

**Clinical Pearls:**
1. GLP-1 receptor agonists, like Exenatide, are an important class of drugs in diabetes management as they mimic the action of endogenous GLP-1, promoting insulin release in a glucose-dependent manner.
2. In the context of diabetes, understanding the origin of Exenatide and its primary action is crucial for proper understanding of its mechanism of action and clinical application.